Agència de Salut Pública de Barcelona-ko ikertzaileekin lankidetzan egindako argitalpenak (10)

2022

  1. Effect of COVID-19 Pandemic on Invasive Pneumococcal Disease in Children, Catalonia, Spain

    Emerging Infectious Diseases, Vol. 28, Núm. 11, pp. 2321-2325

2021

  1. Necrotizing pneumonia due to Streptococcus pneumoniae in children during the period of non-systematic use of PCV13 in Catalonia, Spain

    Enfermedades Infecciosas y Microbiologia Clinica, Vol. 39, Núm. 10, pp. 486-492

2020

  1. Impact of the 13-valent conjugated pneumococcal vaccine on the direct costs of invasive pneumococcal disease requiring hospital admission in children aged < 5 years: A prospective study

    Vaccines, Vol. 8, Núm. 3, pp. 1-17

2016

  1. Vaccine failures in patients properly vaccinated with 13-valent pneumococcal conjugate vaccine in Catalonia, a region with low vaccination coverage

    Pediatric Infectious Disease Journal, Vol. 35, Núm. 4, pp. 460-463

2015

  1. Effectiveness of non-pharmaceutical measures in preventing pediatric influenza: A case-control study

    BMC Public Health, Vol. 15, Núm. 1

  2. Estimation of the invasive disease potential of Streptococcus pneumoniae in children by the use of direct capsular typing in clinical specimens

    European Journal of Clinical Microbiology and Infectious Diseases, Vol. 34, Núm. 4, pp. 705-711

2013

  1. Are risk factors associated with invasive pneumococcal disease according to different serotypes?

    Human Vaccines and Immunotherapeutics

  2. Clinical features of influenza disease in admitted children during the first postpandemic season and risk factors for hospitalization: A multicentre Spanish experience

    Clinical Microbiology and Infection, Vol. 19, Núm. 3

  3. Risk factors for invasive pneumococcal disease in a community with a high proportion of non vaccine serotypes

    Vaccine, Vol. 31, Núm. 6, pp. 960-966

2011

  1. Effectiveness of 7-valent pneumococcal conjugate vaccine in the prevention of invasive pneumococcal disease in children aged 7-59 months. A matched case-control study

    Vaccine, Vol. 29, Núm. 48, pp. 9020-9025